STAT+: Pharma’s Reputation Among Patient Groups Rose Last Year, but Concerns Remain over Access and Pricing

Why It Matters

The uptick demonstrates that patient‑focused strategies can boost trust, but lingering access and pricing issues could erode goodwill and shape future market and regulatory dynamics.

Key Takeaways

• Reputation rose to 57% among 2,400 patient groups worldwide
• Patient centricity and safety identified as primary improvement drivers
• 47 pharma firms evaluated; still below 2022’s 60% benchmark
• Access and pricing concerns remain prominent among patient advocates
• Survey spans 35 countries, reflecting global sentiment trends

Pulse Analysis

The pharmaceutical sector has long wrestled with a volatile public image, and the latest STAT+ survey provides a nuanced snapshot of where the industry stands. By polling over 2,400 patient advocacy groups across 35 nations, the study reveals a modest climb to a 57% “excellent” or “good” reputation rating for drugmakers. While this marks an improvement over the previous year, it still lags behind the 60% high point recorded in 2022, underscoring that reputation gains are incremental and can quickly reverse if underlying issues are not addressed.

Key to the slight rebound were two themes: patient centricity and safety. Companies that have invested in real‑world evidence programs, transparent clinical trial data, and direct patient engagement platforms are being recognized for putting patient needs at the forefront. Simultaneously, heightened focus on pharmacovigilance and rapid response to safety signals has reassured many advocacy groups. However, the survey also flags persistent anxieties around drug access and pricing, with many respondents questioning whether cost‑containment measures are sufficient to ensure equitable treatment availability.

For industry leaders, investors, and policymakers, these findings signal a strategic crossroads. Enhancing patient‑centric practices can continue to lift perception, but without concrete solutions to affordability and supply chain barriers, reputational gains may plateau. Stakeholders are likely to see increased pressure for value‑based pricing models, greater transparency in price setting, and collaborative frameworks that align commercial goals with patient outcomes. The next reporting period will reveal whether the sector can translate these incremental reputation improvements into lasting trust and sustainable growth.